J Korean Med Sci.  2021 Apr;36(14):e107. 10.3346/jkms.2021.36.e107.

Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience

• Kim SH
• Wi YM
• Yun SY
• Ryu JS
• Shin JM
• Lee EH
• Seo KH
• Lee SH
• Peck KR

• KMID: 2514898
• DOI: http://doi.org/10.3346/jkms.2021.36.e107

Abstract

Coronavirus disease 2019 vaccinations for healthcare workers (HCWs) have begun in South Korea. To investigate adverse events (AEs) of the first dose of each vaccine, any symptom was collected daily for seven days after vaccination in a tertiary hospital. We found that 1,301 of 1,403 ChAdOx1 nCoV-19 recipients and 38 of 80 BNT162b2 recipients reported AEs respectively (90.9% vs. 52.5%): injection-site pain (77.7% vs. 51.2%), myalgia (60.5% vs. 11.2%), fatigue (50.7% vs. 7.5%), headache (47.4% vs. 7.5%), and fever (36.1% vs. 5%; P < 0.001 for all). Young HCWs reported more AEs with ChAdOx1 nCoV-19 than with BNT162b2. No incidences of anaphylaxis were observed. Only one serious AE required hospitalization for serious vomiting, and completely recovered. In conclusion, reported AEs were more common in recipients with ChAdOx1 nCoV-19 than in those with BNT162b2. However, most of the reported AEs were mild to moderate in severity. Sufficient explanation and preparation for expected AEs required to promote widespread vaccination.

Keyword

Coronavirus Disease 2019; Vaccine; Adverse Event; ChAdOx1 nCoV-19 Vaccine; BNT162b2 mRNA COVID-19 Vaccine

Figure

• 

  Fig. 1 Incidence of reported adverse events in each vaccine group.AEs = adverse events.**P < 0.005.

• 

  Fig. 2 Proportions of reported adverse events in ChAdOx1 nCoV-19 vaccine recipients stratified by age (A). Positive responses rates of each adverse events in ChAdOx1 nCoV-19 vaccine recipients on post-vaccination days 0–7 (B).*P < 0.05; **P < 0.005.

Reference

1. World Health Organization. WHO coronavirus (COVID-19) dashboard. Updated 2021. Accessed March 21, 2021. https://covid19.who.int.

2. Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020; 586(7830):516–527. PMID: 32967006.

3. Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020; 383(25):2439–2450. PMID: 33053279.

4. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020; 383(27):2603–2615. PMID: 33301246.

5. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021; NEJMoa2101765.

6. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249):467–478. PMID: 32702298.

7. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021; 396(10267):1979–1993. PMID: 33220855.

8. Voysey M, Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021; 397(10269):99–111. PMID: 33306989.

9. Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021; 397(10277):881–891. PMID: 33617777.

10. Gee J, Marquez P, Su J, Calvert GM, Liu R, Myers T, et al. First month of COVID-19 vaccine safety monitoring - United States, December 14, 2020-January 13, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(8):283–288. PMID: 33630816.

11. The COVID-19 Vaccination Response Promotion Team. Adverse Event Management Guidelines after Coronavirus Disease 19 Vaccination. Cheongju: Korea Centers for Disease Control and Prevention;2021. p. 90.

12. European Medicines Agency. Updated 2021. Accessed April 18, 2021. https://www.ema.europa.eu.